Skip to main content

Summary

at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution.

Details

The investigators propose to randomize at the kebele level, which consist of approximately 15 villages, 4,000 residents, and are served by a single primary school. Eighty kebeles will be randomized to one of four arms: 1) annual mass azithromycin distribution per WHO guidelines (Annual); 2) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years (Core Group—Age); 3) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years with a positive chlamydial PCR test (Core Group—PCR); or 4) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years positive for conjunctival inflammation as assessed from annual photography (Core Group—TI). The primary outcome for the trial will be the ocular chlamydia prevalence at 12, 24, and 36 months. Secondary outcomes will include bacterial load of ocular chlamydia via quantitative PCR, the prevalence of clinically active trachoma assessed at 12, 24, and 36 months, and pneumococcal macrolide resistance.

Keywords

Trachoma Azithromycin Mass Drug Administration Antibiotic Resistance

Eligibility

You can join if…

  • All individuals in all communities will be eligible for annual mass azithromycin distribution per WHO guidelines.

You CAN'T join if...

  • Those who do not consent.

Locations

  • UCSF Proctor Foundation in progress, not accepting new patients
    San Francisco, California, 94143, United States
  • The Carter Center not yet accepting patients
    Addis Ababa, Ethiopia

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03335072
Phase
Phase 4
Lead Scientist
Tom M Lietman
Study Type
Interventional
Last Updated
November 7, 2017